Tuesday, February 2, 2021

Private Jets Represent Growth Area

As the head of Jets.com, entrepreneur Edgar Alacan coordinates private charter flights in aircraft that are reliable, well maintained, and meet strict safety standards. Edgar Alacan’s company is positioned within an industry that continues to expand as more people turn toward the convenience of private jet travel.


As reported by Crain’s Chicago Business in early 2021, private jets represent a bright spot within a broader aerospace sector that has been impacted by the pandemic and commercial travel restrictions. One prominent example of this growth is Textron, Inc., which manufactures iconic Cessna jets and Beechcraft turboprops. Textron reported analyst expectations exceeding profits during the fourth quarter of 2020.

This was driven by numerous new orders for private planes, with General Dynamics Corp., the maker of the Gulfstream, achieving a 0.96 book-to-bill ratio. This reflects a situation in which existing orders are shipped out at the same rate as their backlog is replenished. It significantly outpaces sales results of the ailing commercial aircraft manufacturer Boeing, which had one of its poorest years on record in 2020.

Friday, January 15, 2021

Pietro’s Fight Raises Funds for Duchenne Muscular Dystrophy Research


The co-founder of Jets.com, Edgar Alacan oversees sales for the company he has expanded from a startup to a thriving operation with $40 million in annual revenue. Apart from his professional responsibilities, Edgar Alacan serves as a board member for Pietro’s Fight, a charitable organization committed to fighting Duchenne muscular dystrophy.


Founded by Dayna and Manni Scarso after their son Pietro’s diagnosis, Pietro’s Fight raises money to fund transitional research. Working with the world’s leading scientists, the organization aims to accelerate the clinical trial process in order to make life-saving drugs accessible to young boys with Duchenne.

Thanks in part to funding from organizations like Pietro’s Fight, gene-based therapies and RNA-based technology have increasingly been used to extend life expectancies for children with Duchenne, while new therapies such as antisense-mediated exon skipping continue to show promise for treating dystrophic muscle. To read about Pietro’s family’s journey or to learn more about Duchenne muscular dystrophy, visit www.pietrosfight.org.